-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ASN-90 in Progressive Supranuclear Palsy
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ASN-90 in Progressive Supranuclear Palsy report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ASN-90 in Progressive Supranuclear Palsy Drug Details: ASN-90 is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – TG-1042 in Basal Cell Carcinoma (Basal Cell Epithelioma)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - TG-1042 in Basal Cell Carcinoma (Basal Cell Epithelioma) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. TG-1042 in Basal Cell Carcinoma (Basal Cell...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – TG-1042 in Cutaneous B-Cell Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - TG-1042 in Cutaneous B-Cell Lymphoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. TG-1042 in Cutaneous B-Cell Lymphoma Drug Details: TG-1042 (ASN-002) is...
-
Company Insights
NewiDEAL – Competitor Profile
iDEAL - a market leader in Dutch third-party payment services—was established by payment systems provider Currence in 2005. iDEAL offers online payments for Dutch domestic and international shoppers, enabling them to pay for online purchases directly from their bank accounts. iDEAL also enables consumers to carry out other transactions such as utility bill payments, mobile top-ups, and donations. It generates business by offering five types of transactions: domestic ecommerce payments, cross-border ecommerce payments, payments between consumers, non-ecommerce payments, and buy...
-
Consumer Insights
NewMass Affluent Banking in Western Europe – Regional Breakdown by Market Trends, Investment Preferences and Competitor Benchmarking
Mass Affluent Banking Market in Western Europe Report Overview Western Europe has an attractively large segment of the mass affluent population accounting for over 90% of the liquid asset value invested in the region. Equities and mutual funds are the most popular assets besides private pensions and investment properties. Achieving a financially secure and comfortable retirement is the main financial goal of mass affluents. Hence, a large percentage of them prefer accumulating assets instead of repaying their debts. This indicates...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – TG-1042 in Cutaneous B-Cell Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - TG-1042 in Cutaneous B-Cell Lymphoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. TG-1042 in Cutaneous B-Cell Lymphoma Drug Details: TG-1042 (ASN-002) is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – KRLS-004 in Liver Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - KRLS-004 in Liver Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. KRLS-004 in Liver Cancer Drug Details: KRLS-004 (ASN-004) is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – KRLS-004 in Renal Cell Carcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - KRLS-004 in Renal Cell Carcinoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. KRLS-004 in Renal Cell Carcinoma Drug Details: KRLS-004 (ASN-004) is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Gusacitinib Hydrochloride in Systemic Lupus Erythematosus
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Gusacitinib Hydrochloride in Systemic Lupus Erythematosus report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Gusacitinib Hydrochloride in Systemic Lupus Erythematosus Drug Details: Gusacitinib hydrochloride...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Gusacitinib Hydrochloride in Atopic Dermatitis (Atopic Eczema)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Gusacitinib Hydrochloride in Atopic Dermatitis (Atopic Eczema) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Gusacitinib Hydrochloride in Atopic Dermatitis (Atopic Eczema) Drug Details:...